Avergen Pharmaceuticals' Grant

Avergen Pharmaceuticals raised a round of funding on November 13, 2017. Investors include EIT Health.

Avergen Pharmaceuticals is developing an approach to inhibit mutated proteins in Huntington's disease. In this in vivo efficacy study, Avergen Pharmaceuticals wants to demonstrate that the early lead …

Articles about Avergen Pharmaceuticals' Grant: